QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 23, no. 1 (2004): 34-47
doi: 10.1377/hlthaff.23.1.34
© 2004 by Project HOPE
 
New Online
 * New Issue: China & India
 * Obesity In China
 * Pay Cuts For Medicare Docs
 * Access To Care Woes
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (7)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kleinke, J.D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kleinke, J.D.
Related Collections
* Access To Care
* Pharmaceuticals
* Research And Technology
* Politics

Industry Priorities

Access Versus Excess: Value-Based Cost Sharing For Prescription Drugs

J.D. Kleinke

The preponderance of published medical literature and clinical guidelines compels the expansion of pharmaceutical use among Americans, at the same time that private and public health plans seek to restrict such use. The emerging collision course between the march of medical science and the countermarch of medical policy arises from diverging views about the optimal use of drugs and growing philosophical conflict over the abundance and inequities that characterize the U.S. health care system. The consequent turmoil in the market’s approach to managing drug benefits can be remedied through adoption of a value-based (rather than price-based) approach to pharmaceutical spending.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
D. U. Himmelstein, S. Woolhandler, J. C. Goodman, and R. M. Sade
Our Health Care System at the Crossroads: Single Payer or Market Reform?
Ann. Thorac. Surg., November 1, 2007; 84(5): 1435 - 1446.
[Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
M. E. Chernew, A. B. Rosen, and A. M. Fendrick
Value-Based Insurance Design
Health Aff., March 1, 2007; 26(2): w195 - w203.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
J. C. Goodman
What Is Consumer-Directed Health Care?
Health Aff., November 1, 2006; 25(6): w540 - w543.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
F. Simon
Market Access For Biopharmaceuticals: New Challenges
Health Aff., September 1, 2006; 25(5): 1363 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
N. E. Morden and S. D. Sullivan
States' Control Of Prescription Drug Spending: A Heterogeneous Approach
Health Aff., July 1, 2005; 24(4): 1032 - 1038.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
J.D. Kleinke
Turning Point For The Health Care Blame Cycle?
Health Aff., January 1, 2005; 24(1): 291 - 293.
[Full Text] [PDF]



Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2004 Project HOPE–The People-to-People Organization
Terms and Policies